Philadelphia University + Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Jabbour, Serge

< Back

Profile

saj102

Serge A. Jabbour, DM, FACP, FACE

Contact Dr. Jabbour

Walnut Towers
211 S. Ninth Street, Suite 600
Philadelphia, PA 19107

(215) 955-1925
(215) 928-3160 fax

Medical School

St. Joseph's University, Beirut, Lebanon - 1993

Residency

Cooper Medical Center, Camden NJ

Fellowship

Thomas Jefferson University Hospital

Board Certification

Internal Medicine
Endocrinology, Diabetes & Metabolism

Hospital Appointment

Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital

Awards & Honors

Philadelphia Magazine's Top Docs 2012, 2011

Publications

Most Recent Peer-Reviewed Publications

  1. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study
  2. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial
  3. Durability of response to dapagliflozin: a review of long-term efficacy and safety
  4. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
  5. Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism (Clinical Rheumatology, (2016), 35, 12, (3081-3087), 10.1007/s10067-016-3450-3)
  6. Evaluation and management of medullary thyroid cancer
  7. Diagnosis and management of thyroid lymphoma
  8. Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014
  9. Insulin degludec 200 Units/mL is associated with lower injection frequency and improved patient-reported outcomes compared with insulin glargine 100 Units/mL in patients with type 2 diabetes requiring high-dose insulin
  10. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials
  11. Musculoskeletal manifestations of primary hyperparathyroidism
  12. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
  13. SGLT2 inhibitors
  14. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study
  15. Dapagliflozin in type 2 diabetes: Effectiveness across the spectrum of disease and over time
  16. An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
  17. Incidence and Severity of Pancreatogenic Diabetes After Pancreatic Resection
  18. Dapagliflozin is effective as add-on therapy to sitagliptin with or withoutmetformin: A 24-Week, multicenter, randomized, double-blind, placebo-controlled study
  19. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: A new approach to an old problem
  20. Comment and response to: Dapagliflozin-do we need it registered for type 2 diabetes?